On December 20, 2017, the FDA approved macimorelin (Macrilen), developed by Aeterna Zentaris GmbH, marking a significant milestone as the first endogenous ghrelin mimetic treatment for adult growth hormone deficiency. This oral drug approval opens a new therapeutic category with substantial market implications, potentially shifting prescribing trends within the competitive somatropin landscape.